The apolipoprotein E (apoE) is a classic example of a gene exhibiting pleiotropism. We examine potential pleiotropic associations of the apoE2 allele in three biodemographic cohorts of long-living individuals, offspring, and spouses from the Long Life Family Study, and intermediate mechanisms, which can link this allele with age-related phenotypes. We focused on age-related macular degeneration, bronchitis, asthma, pneumonia, stroke, creatinine, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, diseases of heart (HD), cancer, and survival. Our analysis detected favorable associations of the e2 allele with lower LDL-C levels, lower risks of HD, and better survival. The e2 allele was associated with LDL-C in each gender and biodemographic cohort, including longliving individuals, offspring, and spouses, resulting in highly significant association in the entire sample (b = -7.1, p = 6.6 9 10
Introduction
Insights into genetic susceptibility to age-related processes and health traits could be instructive in translational strategies on extending health span and life span (Olshansky et al. 2007; Sierra et al. 2008) . Particularly, an attractive idea is to find genes, which could influence not just one health trait, but a major subset of them, and, eventually, life span (Franco et al. 2009; Martin et al. 2007) . It is increasingly recognized, however, that genetic influences on complex traits, which are characteristic of post-reproductive age in modern societies, are not straightforward; the complexity is, in large part, due to the elusive role of evolution in these traits (Corella and Ordovas 2014; Kulminski 2013; Vijg and Suh 2005) . For example, geriatric diseases are a relatively new phenomenon from the evolutionary viewpoint. This is because of a very modest life span of even our recent predecessors for whom, for example, world record of mean life span in 1840 was about 45 years (Oeppen and Vaupel 2002) .
The problem of genetic influences on age-related human traits is complicated by at least two relevant factors. The first is the complexity of gene functions in humans, which has evolved over years to maximize fitness of individuals in different environments. In part, the problem of redundancy can be simplified by focusing on genetically more homogeneous intermediate phenotypes, often called endophenotypes (Matteini et al. 2010; Yashin et al. 2010) . The second factor is the elusive role of evolution in these traits. This factor implies that ''diseases are not shaped by selection,'' (Nesse et al. 2012) , i.e., evolution did not fix the molecular basis of age-related disease traits. As a result, genetic influences on these traits can be sensitive to individuals' life course and to compositional changes in populations which often are referred to as biodemographic processes (Vaupel 2010 ). These two factors may interact because endogenous exposures can influence gene functions related to fitness and diseases. As a result, one should expect complex mechanisms linking genes with age-related traits, which may result in various modes of pleiotropy. In this regard, mechanisms are considered in broad sense encompassing different levels of organization starting from the micro level (e.g., genes) and ending at the macro level (e.g., phenotypic expression in specific biodemographic groups).
The apolipoprotein E (apoE) is a classic example of a pleiotropic gene, which participates in many cellular functions such as plasma lipoprotein metabolism, oxidative processes, inflammation, macrophage, glial cell and neuronal cell homeostasis, adrenal function, central nervous system physiology (Mahley and Rall 2000) . While participating in these critical processes, common apoE alleles (e2, e3, and e4) can contribute significantly to the pathobiology of aging and age-related traits but this contribution can be complicated by biodemographic factors discussed above (Kulminski et al. 2014 .
Human epidemiological and longitudinal studies suggest that the apoE alleles affect age-related traits (Burt et al. 2008; Mahley et al. 2009; Suri et al. 2013) . For example, studies suggest that the apoE2 allele might be protective against cardiovascular diseases (CVD) (Song et al. 2004) , Alzheimer disease (AD) (Corder et al. 1994) , and mortality (Mahley and Rall 2000) . In contrast, the apoE4 allele can confer risk of Alzheimer disease (Corder et al. 1993 ) and decrease survival chances (Christensen et al. 2006; Kulminski et al. 2014) .
The analyses of pleiotropy and mechanisms linking genes with age-related traits is important given the goal of translation of genetic discoveries into health care. Gaining insights into the connections between genes and age-related traits could help in determining population groups who are at risk for these traits. This could help us understand factors and mechanisms mediated by genes and endophenotypes and tailor disease prevention strategies and novel therapeutic approaches.
In this study, we use information on 4659 genotyped participants of the Long Life Family Study (LLFS), which includes cohorts of long-living parents, their offspring, and spouses of parents and offspring, to address two interlinked questions. First, we investigate whether the apoE2 allele can show pleiotropic effects given a broad array of age-related phenotypes measured in the same study (see ''Methods'' section). Second, we investigate potential role of endophenotypes in connections between the e2 allele and downstream phenotypes in different cohorts of the LLFS population.
Methods

Data
The LLFS collected data at four field centers (three in the U.S. and one in Denmark) on families showing exceptional familial longevity. The study eligibility criteria has been described elsewhere (Pedersen et al. 2006; Sebastiani et al. 2009; Yashin et al. 2010) . Briefly, in the U.S., the families eligible for the LLFS must have two living siblings aged 80? years, two living offspring of one or more of the siblings, and a living spouse of one of the offspring. In addition, the family must demonstrate exceptional longevity based on a Family Longevity Selection Score, which is a summary-measure based on the survival experience of the oldest living generation of siblings relative to what would be expected based on birth cohort life tables (Sebastiani et al. 2009 ).
In Denmark, individuals who would be aged 90? years during the study recruitment period were first identified in the Danish National Register of Persons (Pedersen et al. 2006) . Then, using information on the place of birth and the names, parish registers available in regional archives were searched to locate the parents of the elderly individuals in order to identify sibships. The identified subjects were contacted to further assess the family's eligibility for participation in the LLFS using criteria parallel to that used in the U.S.
Information from the 4954 U.S. and Danish LLFS participants was collected using similar questionnaires and in-home physical examinations at baseline between 2006 and 2009. Information on onsets of diseases was assessed retrospectively at baseline from self-reports and prospectively during ongoing follow up (available currently through 2014). Biospecimens were collected at baseline. Genotyping of the apoE polymorphism was conducted using procedure detailed elsewhere (Schupf et al. 2013) . The data include information on the apoE e2/e3/e4 polymorphism for the 4659 LLFS participants.
Biodemographic structure of the LLFS LLFS includes long-living (LL) individuals (N = 1384, probands and siblings), their offspring (N = 2321), and 954 spouses of long-living individuals (N = 177) and spouses of offspring (N = 777). The long-living individuals (mean age and standard deviation are 90.3 ± 6.5 years) were selected based on a history of familial longevity (see the above section). They were also subject to strong survival selection given their old age. Their offsprings were also selected based on a history of familial longevity.
Unlike LL individuals and their offspring, however, the spouses were not selected based on a history of familial longevity. Given about the same young-old age of the offspring (60.5 ± 8.2 years) and spouses (65.0 ± 12.1 years), these cohorts were under about the same weak survival selection. Thus, these three groups represent three biodemographic cohorts with potentially different survival chances.
Genotypes
Genotyping of the APOE alleles was conducted at the Biomedical Genomics Center at the University of Minnesota using procedures detailed elsewhere (Schupf et al. 2013) . In brief, genotyping of APOE was based on SNPs rs7412 and rs429358 using the Taqman genotyping platform and concordance among genotypes for both SNPs was 100 % based on blinded duplicates. We characterize the effects of the apoE2 allele (defined as e2/e2, e2/e3, or e2/e4 genotypes) on a number of traits contrasted by common homozygous genotype e3/e3. Distribution of six genotypes of the apoE locus in the entire sample of the LLFS participants as well in subsamples of the LL individuals, offspring, and spouses is given in Supplementary Table 1.
Phenotypes and endophenotypes
The focus of the study was on selected phenotypes (outcomes) and endophenotypes (intermediate phenotypes) including age-related macular degeneration (AMD), bronchitis, asthma, pneumonia, stroke, creatinine, LDL-C, high-density lipoprotein cholesterol (HDL-C), diseases of heart (HD), cancer, and death. HD included coronary heart disease, atrial fibrillation, heart failure, coronary angioplasty, or coronary artery bypass. Cancer included all sites. These traits could be sensitive to the e2 allele according to prior research (more details are given in the ''Discussion'' section). Depending on the analyses used in the study, the same biomarker/disease could be an endophenotype or a phenotype. For example, lipids were outcomes in the analyses of their associations with the e2 allele but they were endophenotypes in the analyses of the associations of this allele with diseases. Likewise, diseases were endophenotype in the analyses of the associations with risks of death. 
Analysis
Associations of the e2 allele with quantitative outcomes were characterized by a mixed effects linear regression model with adjustment for potential familial clustering. Measurements of lipids and creatinine were log transformed to offset potential bias due to skewness of their frequency distributions. We used information on fasting (fasted less than 8 h or 8? h) and lipid-lowering treatment (taken lipid-lowering drugs or not) to investigate whether these conditions modulated the associations. Genotype-specific proportions of these factors are given in Supplementary  Table 1 .
The risks of the selected diseases and death for carriers of the e2 allele compared with carriers of the e3/e3 common genotype were evaluated using the Cox proportional hazard regression model. Information on both prospective and retrospective onsets of diseases collected in the LLFS was used in these analyses. The use of retrospective onsets in a failure-type model is justified in (Prentice and Breslow 1978) . These analyses provide estimates of the effects in a given population. The time variable in the Cox regression analyses was the age at onset of a trait or the age at right censoring. We used robust sandwich estimator of variances in the Cox model to adjust for familial clustering.
The analyses were conducted for men and women separately. Given differences in proportions of carriers of the apoE genotypes across family groups (i.e., LL, offspring, and spouses, see Supplementary Table 1) , the analyses were conducted in each family group separately, when applicable. Because of small number of cases of AMD, asthma, bronchitis, and stroke for carriers of the e2 allele (Supplementary Table 1 ), the analyses with these diseases were conducted using data for all family groups pooled together.
We evaluated potential mediating role of endophenotypes (e.g., LDL-C) in the associations of the e2 allele with phenotypes (e.g., diseases of heart) by adjusting the models by the endophenotypes.
All statistical tests were adjusted for field centers and birth cohorts measured by age at baseline. Other adjustments were explicitly stated in the text, when applicable. Statistical analyses were conducted using SAS (release 9.3, Cary, NC, USA).
Results
The following sections provide the associations of the e2 allele with selected biomarkers as well as with the risks of diseases and mortality highlighting significance of these associations and mediating role of endophenotypes in the downstream phenotypes. We considered: (i) lipids (LDL-C and HDL-C) and lipidlowering therapy as endophenotypes for diseases of heart and (ii) lipids, lipid-lowering therapy and diseases as endophenotypes for mortality.
Associations of the e2 allele with diseases of heart For diseases of heart, we observed protective effects of the e2 allele in long-living men and women (see Supplementary Table 2 ). Upon pooling data for men and women, this protective effect in the parents' generation became highly significant (Fig. 1a) . Table 2 Associations of the e2 allele with lipids In studies of genetic associations with lipids, it was often assumed that fasting and lipid-lowering therapy might modulate genetic associations and, therefore, the analyses should be corrected for these confounding factors a priori. For example, this may be because lipid-lowering therapy may lower total cholesterol and LDL-C levels. However, while these factors might indeed be associated with lipid levels, it was actually unknown whether associations of specific genetic variants with lipids were modulated by fasting and lipidlowering therapy. Accordingly, we first verified whether fasting and lipid-lowering therapy may modulate associations of the e2 allele with lipids in the LLFS data.
Our analyses showed that fasting made no difference in the associations of the e2 allele with LDL-C and high-density lipoprotein cholesterol (HDL-C) levels (Supplementary Table 3 ). Accordingly, fasting status was disregarded in further analyses. Lipidlowering therapy, however, did affect the associations of the e2 allele with LDL-C but not with HDL-C (Supplementary Table 4 ). For consistency, lipid-lowering therapy was retained in the model. Table 1 showed highly significant protective associations of the e2 allele with LDL-C showing the carriers of the e2 allele having lower LDL-C levels. The effect sizes were remarkably consistent in each family group with somewhat larger absolute sizes in women. Overall, the association of the e2 allele with LDL-C in the entire LLFS sample was highly significant, b = -7.09, p = 6.6 9 10 -44 . Although the associations of the e2 allele with HDL-C attained conventional and suggestive-effect significance in some family groups, these (and the other non-significant) effects showed opposite trends in few other family groups. Superposition of these antagonistic effects results in negligible effect of the e2 allele on HDL-C in the entire LLFS population.
The role of lipids in the association of the e2 allele with diseases of heart Here we examined whether or not the protective associations of the e2 allele with LDL-C (Table 1) mediated protective association of this allele with HD (Fig. 1a) . This analysis helps in clarifying whether or not LDL-C may be in a causal pathway linking the e2 allele with HD. Table 2 showed that adjustment of the model for HD by LDL-C amplified protective effects between the e2 allele and risks of HD in exceptional populations of the long-living parents and their offspring whereas this adjustment weakened the detrimental effect in a population of spouses. These results implied that LDL-C did not mediate the protective effect between the e2 allele and HD in the exceptional populations whereas in spouses, LDL-C partly mediated (explained) the detrimental effect between the e2 allele and HD.
Thus, Table 2 demonstrates that: (i) the protective effects of the e2 allele were more characteristic for the exceptional population of long-living individuals and their offsprings than for spouses and (ii) different mechanisms may link the e2 allele with HD in general and exceptional populations. Then, pooling data for the long-living individuals and their offspring, we saw an increase in the protective effect of the e2 allele by about 22 % from RR = 0.73 (p = 2.9 9 10 -3 ) to RR = 0.60 (p = 3.1 9 10 -6 ) in this population (Table 2) . Overall, this estimate implied that exceptional survivors carrying the e2 allele had about 67 % lower risk of having HD compared to carriers of a common e3/e3 genotype at comparable levels of LDL-C.
The role of lipid-lowering therapy in associations of the e2 allele with risks of HD Table 3 showed that lipid-lowering therapy mediates small proportion of the protective association of the e2 allele with HD in long-living parents (5 %) and a larger proportion in their offspring (14 %) and in spouses (17 %). This therapy explained a larger proportion of the protective effects in men (12 %) than in women (3 %) from the exceptional populations. Overall, drugs mediated about 8 % of the protective association of the e2 allele with HD in these exceptional populations of men and women combined. The difference in the effects remained, though nonsignificant as evidenced by overlapping confidence intervals.
Associations of the e2 allele with the risks of death and the role of endophenotypes Protective effects of the e2 allele on survival were observed in male offspring, male spouses, long-living Biogerontology (2016) 17:893-905 897 women, and female spouses (Supplementary Table 5 ). However, marginal significance was attained only in a relatively small sample size of male spouses (RR = 0.33, p = 0.064).
Having observed strong protective effects of the e2 allele on LDL-C (Table 1) and HD (Table 2) , as well as modulating role of lipid-lowering drugs (Table 3) , we examined whether or not these factors could modulate the associations of the e2 allele with risks of deaths. Table 4 showed that LDL-C (Model 2) played an important modulating role improving the protective association of the e2 allele with risks of death in longliving women. This association attained conventional significance largely due to improving the effect size by about 17 % from RR = 0.83 (p = 0.208) to RR = 0.71 (p = 0.022). Protective effect was also improved in male spouses (Table 4) .
HD and lipid-lowering therapy showed minor effect on the associations of the e2 allele with risks of death (Table 4 , compare Models 2 and 3). Other diseases used in the analyses did not affect the estimates (Supplementary Table 6 ).
Associations of the e2 allele with cancer Interestingly, the e2 allele was found to be adversely associated with risks of cancer in male and female spouses (Supplementary Table 2 ). Pooling data for men and women, detrimental effect in spouses attained conventional significance (Fig. 1b) . Figure 1 shows that protective effects of the e2 allele (regardless of their significance) against cancer and HD were consistently observed in exceptional population of long living parents and their offspring. Detrimental effects (again, regardless of their significance) were also consistently seen in the spouses.
Moderate associations of the e2 allele with pneumonia, stroke, and creatinine levels Marginally significant protective association with risk of stroke was observed in men (RR = 0.55, p = 0.055) but not in women (RR = 1.31, p = 0.29) (Supplementary Table 7) . The model was adjusted for field centers, birth cohorts, and lipid-lowering therapy, as well as for sex and family groups, when applicable M & W is men and women, All denotes all family groups combined, LLP denotes long living parents * The effect size beta is evaluated for 100 9 log 10 (lipids)
The risks of pneumonia for carriers of the e2 allele were mixed across sexes and family groups (Supplementary Table 7 ). Detrimental suggestive-effect association (RR = 1.53, p = 0.088) was observed in male spouses. Trend on protective effect of the e2 allele was observed in long living men (RR = 0.77, p = 0.16).
Similarly, the associations of the e2 allele with creatinine levels were mixed across sexes and family groups (Supplementary Table 8 ). The e2 allele seemed to be associated with decreased creatinine levels in male spouses (b = -2.09, p = 0.031) and, in female offspring (b = -1.06, p = 0.058). The results of Model 1 are not the same as in Fig. 1a because individuals with missing information on LDL-C (3.5 %) were excluded from these analyses N total is the sample size. N event is the number of events Non-significant associations of the e2 allele with AMD, asthma, and bronchitis
The analyses did not reveal significant associations of the e2 allele with the risks of age-related macular degeneration (AMD), asthma, or bronchitis either for males or for females (Supplementary Table 7 ). The lack of significance could be a result of the sample size due to small number of disease cases.
Discussion
Allelic variations at the apoE locus have been known to influence various age-related traits such as AD, hyperlipidemia, cardiovascular disease, hemorrhagic stroke and survival. Studies in the recent past have indicated that the apoE2 allele might be protective for survival, associated with decreased levels of serum cholesterol, lower risk of cardiovascular diseases, and has neuroprotective effects against AD, infectious diseases, gastric cancer and other age-related disorders. Prior studies have also provided evidence that the apoE2 allele possesses anti-inflammatory and antioxidant properties and involved in DNA damage response and repair. Despite the evidence for a strong association of apoE2 with health span and longevity, fundamental hurdles to the translation of apoE2 into novel therapeutics include the lack of information on genotype-phenotype relationships and the poor understanding of the functional pathways involved in mediating the protective effects.
In light of these observations, we undertook the current study on the LLFS cohorts to examine two interlinked questions. First, we investigated potential roles of the apoE2 allele in an array of complex agerelated traits including AMD, bronchitis, asthma, pneumonia, stroke, creatinine, LDL-C, HDL-C, HD, cancer, and survival. These traits were selected based on published reports on their association with the apoE polymorphism as discussed in sections below. Second, we examined potential mechanisms linking the e2 allele, endophenotypes, and downstream phenotypes by analyzing modulating role of endophenotypes in the associations of the e2 allele with phenotypes considering the biodemographic structure of the LLFS population. This structure reflects the study design in the selection of the LLFS participants (see more details in ''Methods'' section on ''Biodemographic structure of the LLFS''.
No significant effects of the e2 allele on AMD, asthma, or bronchitis AMD Previously, the e4 allele was reported to have a significant association with a decreased risk of AMD and the e2 allele was reported to be possibly associated with an increased risk of AMD (de Jong 2006; The results of the Model 1 are not the same as in Supplementary Table 5 because individuals with missing information on LDL-C (3.5 %) were excluded from these analyses N total is the sample size, N event is the number of events Kulminski et al. 2008; Thakkinstian et al. 2006) . Some studies report, however, suggestive-effect protective associations (Klaver et al. 1998) whereas the other show non-significant effect of the e2 allele (Schultz et al. 2003) . Our analyses show no significant associations of the e2 allele with AMD in the LLFS. Small number of AMD cases for the e2 carriers does not allow us to examine whether or not the lack of the detrimental effect of the e2 allele on AMD could be due to exceptional nature of the LLFS population.
Asthma and bronchitis
The apoE gene has been hypothesized to play a role in asthma and bronchitis based on studies on humanized apoE mice. (Yao et al. 2012) . huApoE alleles differentially modified key pathogenic responses to nasal repeated house dust mite challenges, which can be stratified, in rank order of increasing disease severity, e3 \ e4 \ e2. Compared with muApoE, the huApoE3 allele confers a protective phenotype with reduced airway hyperreactivity, mucous cell metaplasia, and airway inflammation, whereas the huApoE4 allele has an intermediate asthma phenotype with selectively attenuated AHR and serum IgE production.
However, the results of our analyses do not support connection of the e2 allele with bronchitis and asthma in the LLFS participants. Again, small number of the disease cases prevents gaining insights on the role of exceptionality of the LLFS population.
The e2 allele and pneumonia, stroke, and creatinine levels
Pneumonia
There is evidence that apoE could play a role in reducing susceptibility to three categories of infectious agents: viruses, bacteria, and protozoan parasites (Mahley and Rall 2000) . Furthermore, the apoE gene may influence both innate and acquired immunity in a mouse model (Roselaar and Daugherty 1998) . The susceptibility of apoE knock-out mice to Klebsiella pneumoniae and lowered inhibition of pro-inflammatory cytokine response has also been demonstrated (de Bont et al. 1999 ).
Our analyses suggest that, potentially, the e2 allele can influence the risks of pneumonia in the LLFS participants. However, inconsistent effect directions in the LLFS cohorts suggest that these effects can be sensitive to such biodemographic processes as survival selection with stronger sensitivity in men.
Stroke
A meta-analysis of the associations of the apoE genotypes with stroke showed that the e2/e3 genotype was associated with reduced risks (Khan et al. 2013) . Our analyses support this protective association but only for men carrying the e2 allele.
Creatinine
ApoE exerts a major role in the pathogenesis and the progression of a variety of renal diseases, as well as in the atherosclerotic complications associated with them. Chronic kidney disease (CKD) as measured by estimated glomerular filtration rate (eGFR) using creatinine and cystatin is known to affect more than 30 % of older adults (Coresh et al. 2007) . It is believed that development and progression of CKD is multifactorial and contributed by genetic variation, diabetes, hypertension, elevated triglycerides and low HDL-C (Hunsicker et al. 1997) . There is still controversy on the effects of apoE alleles in renal diseases. Some studies have provided evidence that apoE2 allele carries a genetic risk for renal diseases whereas others have shown that the apoE4 allele is a risk factor for the progression of renal failure (Araki et al. 2003; Eto et al. 1995; Kimura et al. 1998; Oda et al. 1999) . The e4 allele is found to be associated with a lower risk of CKD in adjusted and unadjusted analyses using creatinine as biomarker (Seshasai et al. 2012 ). Liberopoulos et al. (Liberopoulos et al. 2004 ) from their studies on healthy individuals reported that individuals carrying apoE2 allele have increased levels of serum creatinine and reduced GFR compared with both e3 and e4 subjects.
Our results provide mixed evidence of the associations of the e2 allele with creatinine levels across different LLFS cohorts. Significant and marginally significant associations were observed for male spouses and female offspring, respectively, meaning that the e2 allele is associated with lower creatinine levels. These associations could be interpreted as e2 being a favorable protective variant for kidney diseases in the LLFS cohort.
Trade-offs in the effects of the e2 allele on HD and cancer
Diseases of heart
Two major meta-analyses of the associations of apoE with HD show trends towards a protective role of the e2 allele (Song et al. 2004; Wilson et al. 1996) . The results of our analyses, which did not focus on modulating role of endophenotypes, show that the e2 allele can be protective against HD. A novel important insight was that this protective effect was strongly sensitive to the biodemographic factors. This means that the protective effect was pronounced in the exceptional populations of parents (RR = 0.72, p = 4.8 9 10
-3 in men and women combined) and male offspring (RR = 0.73, p = 0.29) whereas in the LLFS spouses (who were not selected for chances of exceptional longevity) the effect of the e2 allele was detrimental (RR = 1.28, p = 0.28).
Cancer
Evidence from prior studies on the associations of the apoE gene with cancer are conflicting and sparse with an unclear role of each allele (Anand et al. 2014) . The presence of the e2 allele was hypothesized previously to be a risk factor for cancer (Katan 1986) . Some studies supported this hypothesis. Indeed, an increased risk of colon cancer for male carriers of the e2/e3 genotype compared to the e3/e3 genotype was, reported in (Watson et al. 2003) . Other studies did not support that hypothesis. For example, no significant associations of the apoE genotypes with prostate cancer were reported in (Liu et al. 2015) . Protective effect of the e2 allele was reported against gastric cancer (De Feo et al. 2012) .
Our results support a detrimental effect of the e2 allele on cancer in men and women combined. However, this effect was characteristic for a sample of a general population represented by the LLFS spouses (Fig. 1b) . This finding suggests that the lack of detrimental effect of the e2 allele on cancer in the exceptional populations can be due to health-protective genetic profiles of individuals in those populations. This protective profile can explain the observed trade-off of the effects of the e2 allele on HD and cancer seen in a sample of spouses and the exceptional populations.
The e2 allele and lipid levels
The apoE gene is known to influence lipid metabolism (Eichner et al. 2002) . The apoE protein is involved in transport of cholesterol and triglycerides in blood as very low density lipoprotein and its conversion to LDL-C (Hauser et al. 2011) . The e2 allele is associated with lower cholesterol levels in most populations (Eichner et al. 2002) .
Our results support these findings by showing highly significant associations of the e2 allele with lower LDL-C levels in different populations regardless of their biodemographic structure (in populations of men and women and in populations characterized by different survival chances, Table 1 ). However, the e2 allele shows mostly non-significant populationspecific effects on HDL-C.
The e2 allele, HD, LDL-C, and lipid-lowering therapy Of the associations with the age related diseases, the e2 allele shows the most convincing protective associations with HD. This protective effect was, however, limited to the LLFS exceptional populations. In a population of the LLFS spouses, the e2 allele shows a trend towards adverse association (nonsignificant) with HD.
The e2 allele is also found to be strongly associated with lower LDL-C levels suggesting a protection against HD (Eichner et al. 2002) . These protective associations of the e2 allele with LDL-C and HD could imply a causal pathway from e2 to HD through LDL-C. We show that this is not the case (Table 2 ). In fact, we see that the protective effect of the e2 allele on HD strengthened by 22 % (RR = 0.73 to RR = 0.60) and its significance improved by three order of magnitude (p = 2.9 9 10 -3 to p = 3.1 9 10 -6 ) in exceptional populations.
Lipid-lowering therapy tends to decrease LDL-C concentrations. Accordingly, it may contribute to causal pathways from e2 to HD through LDL-C. Our analyses suggest that the effect of this therapy is small explaining about 8 % of the protective effect between the e2 allele and HD in the exceptional populations (Table 3) . Accordingly, these results suggest that the lipid-lowering therapy is not a major protective factor against HD in carriers of the e2 allele in the exceptional populations.
Thus, the e2 allele is protective against HD in populations of the LLFS parents and their offspring, who were selected according to their chances of exceptional survival, whereas it can be unfavorable for HD in the LLFS spouses, who were not selected for exceptional survival.
Epidemiological studies suggest that long-living individuals can have biological basis to stay in good health and live long lives, although the nature of this basis remains unclear (Govindaraju et al. 2015) . In part, good health and long lives can be due to favorable genetic factors (e.g., apoE, apoC3, FOXO3a, CETP, IGF genes). Partly, beneficial biological basis can be due to adaptation to specific environments [e.g., centenarians are found at a greater frequency in specific locations called ''blue zones'' (Poulain et al. 2013) ]. The finding of antagonistic effects of the e2 allele in populations of individuals, who were selected according to different survival chances (i.e., longliving individuals and their offspring vs. spouses) but shared the same environment, suggests that the LLFS long-living individuals and their offspring may have beneficial genetic profile (complementing the apoE2 allele) helping them in enhancing their health span (life span free of HD in the present study). Weak sensitivity of beneficial effects of the e2 allele to lipidlowering therapy along with the lack of favorable effect between the e2 allele and HD in spouses indicates that this beneficial genetic profile is either weakly sensitive to lifestyle and environmental factors or it interacts differently with these exposures (Rajpathak et al. 2011 ).
The e2 allele, endophenotypes, lipid-lowering therapy, and life span Studies show that apoE can be associated with longevity and survival. The e4 allele is typically associated with higher mortality risks whereas the e2 allele is considered as protective (Christensen et al. 2006) . Survival is a very complex phenotype which summarizes the entire life course of individuals and absorbs a variety of endophenotypes. Accordingly, if the e2 allele is associated with endophenotypes (HD and LDL-C in this case), then, associations with survival (if any) may or may not be mediated by the associations with these endophenotypes.
We found that the e2 allele was not significantly associated with survival in any of the LLFS cohorts, although, protective trend was seen in long-living women, male offspring, and spouses. We found, however, that LDL-C strongly moderated the effect of the e2 allele on survival in long-living women making this protective association to attain nominal significance. This finding suggest that, similarly to the case of HD, this allele acts on LDL-C and on survival through different mechanisms. The lack of a role of other endophenotypes (HD, cancer, stroke, asthma, AMD, bronchitis, and pneumonia) and lipid-lowering therapy in the protective association of the e2 allele with survival implies that this association is likely mediated by a third mechanism, which is independent of the LDL-C-and HD-related mechanisms.
It should be emphasized that the LLFS is a familybased cohort study examining the genetic and nongenetic factors associated with exceptional familial longevity (see ''Methods'' section). Long-lived individuals, their siblings and their offspring and spouses were recruited for an examination that characterized key intermediate phenotypes of longevity, including major chronic diseases, risk factors, and physical and cognitive function. The LLFS cohort is, therefore, a highly selected group of exceptional families and not representative of the overall general population. Thus caution is needed when interpreting and extrapolating these results to other populations as they have limited generalizability under the hypothesis of ''pure genetic'' component in complex traits.
Conclusions
Our analyses of the role of the apoE2 allele in agerelated traits showed associations of this allele with many age-related traits revealing both protective and detrimental roles. ApoE2 was found to have no associations with AMD, bronchitis, and asthma in LLFS. It appears that the e2 allele can influence the risks of pneumonia, but its effects may be sensitive to biodemographic factors. The e2 allele shows protection against stroke (in men only) and is found to be associated with lower creatinine levels in some biodemographic groups. The e2 allele shows tradeoff effects with protective role against HD and detrimental role in cancer in the LLFS cohorts with different survival chances. The e2 allele shows favorable associations with LDL-C, HD, and survival through three mechanisms. One mechanism (the LDL-C-related) is independent of biodemographic structure of the LLFS population. The other two (HD-and survival-related) mechanisms are distinctive of the LDL-C-related mechanism because they are sensitive to this structure, i.e., both of them are pronounced in the populations with chances of exceptional survival. The latter two mechanisms are further subdivided with the survival-related mechanism being gender sensitive whereas the HD-related mechanism is not. This implies that, potentially, favorable biomarker profile, longer health span, and longer life can be modulated by the same gene but in an independent manner. The latter implies that the effect of the e2 allele could be modulated by other factors of genetic and/or nongenetic origin.
Our results indicate an important role of biodemographic factors in the associations of the apoE2 allele with most complex traits considered in this analysis. We believe that by reconciling contradictions on the metabolic effects of e2 and focusing on the protective functions of apoE may open up new avenues for therapeutic target identification for healthy aging.
